ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

Laura Z. Rassenti, Lang Huynh, Tracy L. Toy, Liguang Chen, Michael J. Keating, John G. Gribben, Donna S. Neuberg, Ian W. Flinn, Kanti R. Rai, John C. Byrd, Neil Elliot Kay, Andrew Greaves, Arthur Weiss, Thomas J. Kipps

Research output: Contribution to journalArticle

756 Citations (Scopus)

Abstract

BACKGROUND: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV H) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV H but lack expression of ZAP-70. METHODS: We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV H gene. We then investigated the association between the results and the time from diagnosis to initial therapy. RESULTS: We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV H gene (71 percent), but in only 24 of the 143 patients with a mutated IgV H gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV H gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV H gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV H genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV H gene and 7.1 years in those with an unmutated IgV H gene (P<0.001). CONCLUSIONS: Although the presence of an unmutated IgV H gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.

Original languageEnglish (US)
Pages (from-to)893-901
Number of pages9
JournalNew England Journal of Medicine
Volume351
Issue number9
DOIs
StatePublished - Aug 26 2004

Fingerprint

Immunoglobulin Heavy Chain Genes
B-Cell Chronic Lymphocytic Leukemia
Disease Progression
Mutation
Genes
ZAP-70 Protein-Tyrosine Kinase
Therapeutics
Immunoglobulin Heavy Chains

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. / Rassenti, Laura Z.; Huynh, Lang; Toy, Tracy L.; Chen, Liguang; Keating, Michael J.; Gribben, John G.; Neuberg, Donna S.; Flinn, Ian W.; Rai, Kanti R.; Byrd, John C.; Kay, Neil Elliot; Greaves, Andrew; Weiss, Arthur; Kipps, Thomas J.

In: New England Journal of Medicine, Vol. 351, No. 9, 26.08.2004, p. 893-901.

Research output: Contribution to journalArticle

Rassenti, LZ, Huynh, L, Toy, TL, Chen, L, Keating, MJ, Gribben, JG, Neuberg, DS, Flinn, IW, Rai, KR, Byrd, JC, Kay, NE, Greaves, A, Weiss, A & Kipps, TJ 2004, 'ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia', New England Journal of Medicine, vol. 351, no. 9, pp. 893-901. https://doi.org/10.1056/NEJMoa040857
Rassenti, Laura Z. ; Huynh, Lang ; Toy, Tracy L. ; Chen, Liguang ; Keating, Michael J. ; Gribben, John G. ; Neuberg, Donna S. ; Flinn, Ian W. ; Rai, Kanti R. ; Byrd, John C. ; Kay, Neil Elliot ; Greaves, Andrew ; Weiss, Arthur ; Kipps, Thomas J. / ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. In: New England Journal of Medicine. 2004 ; Vol. 351, No. 9. pp. 893-901.
@article{76319f3f3ec74f818d9302d7539c36f8,
title = "ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia",
abstract = "BACKGROUND: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV H) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV H but lack expression of ZAP-70. METHODS: We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV H gene. We then investigated the association between the results and the time from diagnosis to initial therapy. RESULTS: We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV H gene (71 percent), but in only 24 of the 143 patients with a mutated IgV H gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV H gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV H gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV H genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV H gene and 7.1 years in those with an unmutated IgV H gene (P<0.001). CONCLUSIONS: Although the presence of an unmutated IgV H gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.",
author = "Rassenti, {Laura Z.} and Lang Huynh and Toy, {Tracy L.} and Liguang Chen and Keating, {Michael J.} and Gribben, {John G.} and Neuberg, {Donna S.} and Flinn, {Ian W.} and Rai, {Kanti R.} and Byrd, {John C.} and Kay, {Neil Elliot} and Andrew Greaves and Arthur Weiss and Kipps, {Thomas J.}",
year = "2004",
month = "8",
day = "26",
doi = "10.1056/NEJMoa040857",
language = "English (US)",
volume = "351",
pages = "893--901",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

AU - Rassenti, Laura Z.

AU - Huynh, Lang

AU - Toy, Tracy L.

AU - Chen, Liguang

AU - Keating, Michael J.

AU - Gribben, John G.

AU - Neuberg, Donna S.

AU - Flinn, Ian W.

AU - Rai, Kanti R.

AU - Byrd, John C.

AU - Kay, Neil Elliot

AU - Greaves, Andrew

AU - Weiss, Arthur

AU - Kipps, Thomas J.

PY - 2004/8/26

Y1 - 2004/8/26

N2 - BACKGROUND: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV H) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV H but lack expression of ZAP-70. METHODS: We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV H gene. We then investigated the association between the results and the time from diagnosis to initial therapy. RESULTS: We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV H gene (71 percent), but in only 24 of the 143 patients with a mutated IgV H gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV H gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV H gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV H genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV H gene and 7.1 years in those with an unmutated IgV H gene (P<0.001). CONCLUSIONS: Although the presence of an unmutated IgV H gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.

AB - BACKGROUND: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV H) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV H but lack expression of ZAP-70. METHODS: We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV H gene. We then investigated the association between the results and the time from diagnosis to initial therapy. RESULTS: We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV H gene (71 percent), but in only 24 of the 143 patients with a mutated IgV H gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV H gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV H gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV H genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV H gene and 7.1 years in those with an unmutated IgV H gene (P<0.001). CONCLUSIONS: Although the presence of an unmutated IgV H gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.

UR - http://www.scopus.com/inward/record.url?scp=4143105617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143105617&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa040857

DO - 10.1056/NEJMoa040857

M3 - Article

C2 - 15329427

AN - SCOPUS:4143105617

VL - 351

SP - 893

EP - 901

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 9

ER -